Table 2.
Characteristics of users of PPIs*, stratified by medication
| Total users n = 10 648 (%) | Omeprazole n = 3939 (%) | Esomeprazole n = 2773 (%) | Pantoprazole n = 1888 (%) | Lansoprazole n = 2668 (%) | Rabeprazole n = 966 (%) | |
|---|---|---|---|---|---|---|
| Mean age (years) | 58.1 ± 16.9 | 61.4 ± 15.7** | 53.3 ± 17.0** | 58.2 ± 16.8 | 59.0 ± 16.7 | 54.8 ± 16.6** |
| Age group | ||||||
| 15–29 years | 594 (5.6) | 119 (3.0)** | 243 (8.8)** | 118 (6.3) | 134 (5.0) | 62 (6.4) |
| 30–44 years | 1894 (17.8) | 514 (13.0)** | 697 (25.1)** | 299 (15.8) | 439 (16.5) | 217 (22.5)** |
| 45–59 years | 2862 (26.9) | 1019 (25.9) | 774 (27.9) | 518 (27.4) | 699 (26.2) | 295 (30.5) |
| 60–74 years | 3341 (31.4) | 1409 (35.8)** | 719 (25.9)** | 615 (32.6) | 871 (32.6) | 262 (27.1) |
| >74 years | 1957 (18.4) | 878 (22.3)** | 340 (12.3)** | 338 (17.9) | 525 (19.7) | 130 (13.5)** |
| Gender | ||||||
| Male | 5477 (51.4) | 2136 (54.2) | 1458 (52.5) | 925 (49.0) | 1291 (48.4) | 491 (50.8) |
| Female | 5171 (48.6) | 1803 (45.8) | 1317 (47.5) | 963 (51.0) | 1377 (51.6) | 475 (49.2) |
| Indication of use for PPI | ||||||
| GERD | 4263 (40.0) | 1218 (30.9)** | 1332 (48.0)** | 855 (45.3)** | 1035 (38.8) | 437 (45.2) |
| Gastroduodenal ulcer | 2635 (24.7) | 1138 (28.9)** | 708 (25.5) | 444 (23.5) | 515 (19.3) | 260 (26.9) |
| Gastroduodenitis | 1407 (13.2) | 574 (14.6) | 294 (10.6)** | 219 (11.6) | 356 (13.3) | 100 (10.4) |
| Other GI diseases § | 1107 (10.4) | 473 (12.0) | 344 (12.4) | 225 (11.9) | 282 (10.6) | 114 (11.8) |
| Gastroprotection | 665 (6.2) | 257 (6.5) | 34 (1.2)** | 87 (4.7) | 312 (11.7)** | 16 (1.7) |
| Not reported | 571 (5.4) | 279 (7.1)** | 63 (2.3)** | 58 (3.1)** | 168 (6.3) | 39 (4.0) |
| Interaction risk (SPC)∧ | ||||||
| No | 10 324 (97.0) | 3737 (94.9) | 2688 (96.9) | 1868 (98.9) | 2584 (96.9) | 937 (97.0) |
| Yes | 324 (3.0) | 202 (5.1)** | 85 (3.1) | 20 (1.1)** | 84 (3.1) | 29 (3.0) |
| Interaction risk (Drugdex)∧ | ||||||
| No | 9690 (91.0) | 3461 (87.9) | 2590 (93.4) | 1769 (93.7) | 2309 (86.5) | 911 (94.3) |
| Yes | 958 (9.0) | 478 (12.1)** | 183 (6.6)** | 119 (6.3)** | 359 (13.5)** | 55 (5.7)** |
Values are numbers (percentages) unless stated otherwise. Legend: GI = gastrointestinal, GERD = Gastroesophageal reflux disease.
*
Patients receiving at least one prescription of PPI during the study period (categories are not mutually exclusive).
**
Statistically significant difference (P < 0.05) in comparison with other users of PPI.
§
Cirrhosis, GI bleeding, GI functional disorders, gastric cancer, GI multiple disease.
∧
Patients receiving at least 1 concomitant prescription of PPI and potentially interacting drugs, according to the Italian SPC of PPIs or Drugdex.